Biogen (BIIB) Expected to Post Quarterly Earnings on Wednesday

Biogen (NASDAQ:BIIB) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to post earnings of $3.13 per share and revenue of $2.4582 billion for the quarter. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Investors are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. The firm had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company’s revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the firm posted $3.02 EPS. On average, analysts expect Biogen to post $13 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Biogen Stock Performance

Shares of NASDAQ BIIB opened at $203.16 on Wednesday. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The business’s 50 day moving average is $199.55 and its two-hundred day moving average is $189.45. The company has a market cap of $29.99 billion, a P/E ratio of 21.80 and a beta of 0.16. Biogen has a 12 month low of $123.38 and a 12 month high of $219.72.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. WFA of San Diego LLC bought a new position in Biogen in the second quarter worth $32,000. Strive Financial Group LLC bought a new stake in Biogen in the 4th quarter valued at $35,000. DV Equities LLC bought a new stake in Biogen in the 4th quarter valued at $36,000. Meeder Asset Management Inc. raised its stake in shares of Biogen by 323.5% in the 4th quarter. Meeder Asset Management Inc. now owns 216 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 165 shares in the last quarter. Finally, Summit Securities Group LLC lifted its holdings in shares of Biogen by 346.9% during the 4th quarter. Summit Securities Group LLC now owns 219 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 170 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Piper Sandler restated an “overweight” rating on shares of Biogen in a research note on Tuesday, July 14th. Sanford C. Bernstein cut their target price on shares of Biogen from $201.00 to $200.00 in a research note on Thursday, April 30th. Evercore initiated coverage on shares of Biogen in a report on Friday, May 15th. They issued an “outperform” rating for the company. Morgan Stanley reduced their price target on shares of Biogen from $224.00 to $222.00 and set an “equal weight” rating for the company in a report on Wednesday, July 8th. Finally, UBS Group upgraded shares of Biogen from a “neutral” rating to a “buy” rating and raised their price target for the stock from $185.00 to $225.00 in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Biogen has a consensus rating of “Moderate Buy” and a consensus price target of $220.57.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.